[go: up one dir, main page]

MA49116A - Compositions pharmaceutiques contenant de l'insuline - Google Patents

Compositions pharmaceutiques contenant de l'insuline

Info

Publication number
MA49116A
MA49116A MA049116A MA49116A MA49116A MA 49116 A MA49116 A MA 49116A MA 049116 A MA049116 A MA 049116A MA 49116 A MA49116 A MA 49116A MA 49116 A MA49116 A MA 49116A
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
compositions containing
containing insulin
insulin
pharmaceutical
Prior art date
Application number
MA049116A
Other languages
English (en)
Inventor
Rosa Rebecca Erritzøe Hansen
Svend Havelund
Susanne Hostrup
Mathias Norrman
Jesper Søndergaard Pedersen
Morten Schlein
Dorte Bjerre Steensgaard
Holger Martin Strauss
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57570394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA49116(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA49116A publication Critical patent/MA49116A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Manipulator (AREA)
MA049116A 2016-12-16 2017-12-15 Compositions pharmaceutiques contenant de l'insuline MA49116A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16204688 2016-12-16

Publications (1)

Publication Number Publication Date
MA49116A true MA49116A (fr) 2020-03-25

Family

ID=57570394

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049116A MA49116A (fr) 2016-12-16 2017-12-15 Compositions pharmaceutiques contenant de l'insuline

Country Status (29)

Country Link
US (6) US20180169190A1 (fr)
EP (2) EP3554534B1 (fr)
JP (2) JP6690062B2 (fr)
KR (2) KR102580007B1 (fr)
CN (2) CN115154591B (fr)
AU (2) AU2017378102B2 (fr)
BR (1) BR112019011761A2 (fr)
CA (1) CA3046583A1 (fr)
CL (1) CL2019001586A1 (fr)
CO (1) CO2019006017A2 (fr)
DK (2) DK3554534T3 (fr)
ES (2) ES2886837T3 (fr)
HR (2) HRP20211281T1 (fr)
HU (2) HUE060149T2 (fr)
IL (2) IL267224B2 (fr)
MA (1) MA49116A (fr)
MX (2) MX380480B (fr)
MY (2) MY194504A (fr)
PE (2) PE20210857A1 (fr)
PH (1) PH12019501363A1 (fr)
PL (2) PL3821905T3 (fr)
PT (1) PT3554534T (fr)
RS (2) RS62295B1 (fr)
RU (1) RU2758367C2 (fr)
SA (2) SA519401933B1 (fr)
SI (1) SI3554534T1 (fr)
TW (2) TWI700092B (fr)
WO (1) WO2018109162A1 (fr)
ZA (3) ZA201903425B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2254906T3 (en) 2008-03-18 2017-01-23 Novo Nordisk As Protease-stabilized acylated insulin analogues
HUE060149T2 (hu) * 2016-12-16 2023-02-28 Novo Nordisk As Inzulint tartalmazó gyógyászati készítmények
CA3122636A1 (fr) 2018-12-11 2020-06-18 Sanofi Analogues d'insuline ayant une affinite de liaison de recepteur d'insuline reduite
AU2020256648A1 (en) * 2019-04-11 2021-11-04 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Multi-receptor agonist and medical use thereof
CN114867743A (zh) 2019-12-10 2022-08-05 赛诺菲 形成磺酰胺与多肽的缀合物的方法
CA3166494A1 (fr) * 2019-12-30 2021-07-08 Gan & Lee Pharmaceuticals Co., Ltd. Derive d'insuline
US20240239859A1 (en) * 2019-12-30 2024-07-18 Gan & Lee Pharmaceuticals Co., Ltd. Long-Acting GLP-1 Compound
JP7424918B2 (ja) * 2020-06-18 2024-01-30 株式会社平和 遊技機
WO2022268208A1 (fr) * 2021-06-25 2022-12-29 甘李药业股份有限公司 Composition pharmaceutique acylée contenant de l'insuline
CN120518744A (zh) * 2025-01-24 2025-08-22 齐鲁制药有限公司 一种胰岛素衍生物、其药物组合物及用途

Family Cites Families (224)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2832685A (en) 1952-05-24 1958-04-29 Crest Foods Co Inc Solubilization of milk proteins
GB894095A (en) 1960-02-08 1962-04-18 Tanaka Shoichi A therapeutic device for personal wear
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3719655A (en) 1969-12-05 1973-03-06 Lilly Co Eli Process for the crystallization of the ammonium and alkali metal salts in insulin
US3950517A (en) 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
US3869437A (en) 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4033941A (en) 1975-12-17 1977-07-05 Eli Lilly And Company Process for purifying glucagon
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
JPS6030650B2 (ja) 1979-10-26 1985-07-17 日本油脂株式会社 座薬基剤組成物
JPS5767548A (en) 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
NL193099C (nl) 1981-10-30 1998-11-03 Novo Industri As Gestabiliseerde insuline-oplossing.
US4839341A (en) 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
DK347086D0 (da) 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4849227A (en) 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
PH23446A (en) 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
US5266310A (en) 1987-09-17 1993-11-30 Boehringer Ingelheim International Gmbh Stabilization of therapeutically active proteins in pharmaceutical preparations
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
AU616205B2 (en) 1988-07-20 1991-10-24 Novo Nordisk A/S Human insulin analogs and preparations containing them
KR0148748B1 (ko) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US5225323A (en) 1988-11-21 1993-07-06 Baylor College Of Medicine Human high-affinity neurotransmitter uptake system
US5716927A (en) 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
KR910700262A (ko) 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
DE3844211A1 (de) 1988-12-29 1990-07-05 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
ATE120762T1 (de) 1989-04-20 1995-04-15 Sinai School Medicine Hepatospezifische insulin-analoga.
CA1340994C (fr) 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Traitement de maladies et d'etats pathologiques
AU6417790A (en) 1989-09-22 1991-04-18 Tsi-Madison Research Institute Method and compositions for one-step cryopreservation of embryos
CA2027930C (fr) 1989-10-19 1998-06-30 Tsuyoshi Miyazaki Complexes polymeriques se comportant comme des sucres
US5179189A (en) 1990-01-19 1993-01-12 Nova Pharmaceutical Corporation Fatty acid terminated polyanhydrides
DK45590D0 (fr) 1990-02-21 1990-02-21 Novo Nordisk As
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
DK158390D0 (da) 1990-07-02 1990-07-02 Novo Nordisk As Nye peptider
WO1992001476A1 (fr) 1990-07-26 1992-02-06 University Of Iowa Research Foundation Nouveaux systemes de liberation de medicaments pour proteines et peptides utilisant de l'albumine comme molecule porteuse
WO1992004893A1 (fr) 1990-09-13 1992-04-02 Smithkline Beecham Corporation Suspensions orales liquides non aqueuses
DK10191D0 (da) 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
US5336782A (en) 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester
WO1998017320A1 (fr) 1991-07-03 1998-04-30 Hyal Pharmaceutical Corporation Utilisation de hyaluronan dans la therapie genique
DK0597007T3 (da) 1991-07-26 1996-11-18 Smithkline Beecham Corp V/O mikroemulsioner
US5268453A (en) 1991-08-08 1993-12-07 Scios Inc. Tissue-selective insulin analogs
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
CZ342492A3 (en) 1991-11-26 1993-06-16 Lilly Co Eli Derivatives of tri-arginine insulin, process of their preparation and a pharmaceutical composition in which said derivatives are comprised
EP0547544B1 (fr) 1991-12-18 1997-03-12 Hoechst Aktiengesellschaft Procédé de préparation de solutions contenant de l'insuline
WO1994008599A1 (fr) 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Appariement d'ions de medicaments pour ameliorer l'efficacite et l'administration
JPH08502492A (ja) 1992-10-16 1996-03-19 スミスクライン・ビーチャム・コーポレイション 治療用ミクロエマルジョン
WO1994008603A1 (fr) 1992-10-16 1994-04-28 Smithkline Beecham Corporation Compositions
EP0684834A4 (fr) 1993-02-17 1996-09-25 Smithkline Beecham Corp Microemulsions contenant des peptides therapeutiques.
WO1994019001A1 (fr) 1993-02-17 1994-09-01 Smithkline Beecham Corporation Micro-emulsions comprenant des peptides therapeutiques
CZ296649B6 (cs) 1993-02-23 2006-05-17 Genentech, Inc. Zpusob výroby stabilizovaného polypeptidového prostredku zahrnující stabilizování polypeptidu protidenaturaci organickými rozpoustedly, jeho príprava a prostredek pro regulované uvolnování polypeptidu
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
DE69428134T2 (de) 1993-09-17 2002-05-02 Novo Nordisk A/S, Bagsvaerd Acyliertes insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
GB9323588D0 (en) 1993-11-16 1994-01-05 Cortecs Ltd Hydrophobic preparation
ATE264096T1 (de) 1994-03-07 2004-04-15 Nektar Therapeutics Verfahren und mittel zur verabreichung von insulin über die lunge
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
GB2296712B (en) 1995-01-05 1999-02-24 British Gas Plc Absorbents for separating nitrogen from a feed gas
CA2215694A1 (fr) 1995-03-17 1996-09-26 Novo Nordisk A/S Derives de l'insuline
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US20010041786A1 (en) 1995-06-07 2001-11-15 Mark L. Brader Stabilized acylated insulin formulations
EP0835129B1 (fr) 1995-06-30 2003-10-29 Novo Nordisk A/S Prevention d'une maladie presentant les caracteristiques du diabete
US20030104981A1 (en) 1995-11-03 2003-06-05 Jelena Mandic Human insulin analogues
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
WO1998001473A1 (fr) 1996-07-05 1998-01-15 Novo Nordisk A/S Procede de production de precurseurs de l'insuline, precurseurs d'analogues de l'insuline et peptides insulinoides
EP0938502B1 (fr) 1996-07-11 2004-10-06 Novo Nordisk A/S Procede selectif d'alcylation
US5981489A (en) 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
EP0821006B1 (fr) 1996-07-26 2004-04-21 Aventis Pharma Deutschland GmbH Dérivés de l'insuline ayant une activité de liaison au zinc augmentée
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US6160541A (en) 1997-01-21 2000-12-12 Lear Automotive Dearborn Inc. Power consumption control for a visual screen display by utilizing a total number of pixels to be energized in the image to determine an order of pixel energization in a manner that conserves power
ATE275963T1 (de) 1997-01-30 2004-10-15 Novartis Pharma Gmbh Ölfreie pharmazeutische zusammensetzung welche cyclosporin enthält
US5898067A (en) 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
US6310038B1 (en) 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
AR012894A1 (es) 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
TR200001050T2 (tr) 1997-10-24 2000-08-21 Eli Lilly And Company Çözünmez insülin bileşimleri
JP2003525846A (ja) 1997-10-24 2003-09-02 ノボ ノルディスク アクティーゼルスカブ ヒトインスリン誘導体の集合体
US20020155994A1 (en) * 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
AU1375199A (en) 1997-11-12 1999-05-31 Alza Corporation Method for decreasing self-association of polypeptides
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
CA2334859A1 (fr) 1998-06-12 1999-12-23 Kings College London Analogue de l'insuline
GB9814172D0 (en) 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
EP1107743B1 (fr) 1998-08-25 2007-06-27 Advanced Inhalation Research, Inc. Formulations proteiques atomisees stables
TW570805B (en) 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
US7030083B2 (en) 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
PL197504B1 (pl) 1998-10-16 2008-04-30 Novo Nordisk As Trwałe stężone preparaty insulinowe do podawania do płuc
US6660715B2 (en) 1998-11-19 2003-12-09 Massachusetts Institute Of Technology Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery
US7425541B2 (en) 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
ATE220917T1 (de) * 1999-01-26 2002-08-15 Lilly Co Eli Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten
AU2879100A (en) 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
WO2000061178A1 (fr) 1999-04-13 2000-10-19 Inhale Therapeutics Systems, Inc. Administration pulmonaire de formulations de poudre seche pour le traitement de l'infecondite
JP2002543092A (ja) 1999-04-27 2002-12-17 イーライ・リリー・アンド・カンパニー 肺投与用インスリン結晶
US6746853B1 (en) 1999-05-19 2004-06-08 Xencor, Inc. Proteins with insulin-like activity useful in the treatment of diabetes
JP2003518917A (ja) 1999-05-19 2003-06-17 ゼンコー 糖尿病の処置に有用なインシュリン様活性を有する新規タンパク質
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
WO2001000674A1 (fr) 1999-06-29 2001-01-04 Eli Lilly And Company Cristaux d'insuline administres par voie pulmonaire
PT1242121E (pt) 1999-12-16 2005-05-31 Lilly Co Eli Composicoes polipeptidicas com estabilidade melhorada
WO2001052937A1 (fr) 2000-01-24 2001-07-26 Medtronic Minimed, Inc. Systeme tampon melange pour la stabilisation de preparations pour polypeptides
DE60120372T2 (de) 2000-03-24 2007-07-05 Genentech Inc., San Francisco Verwendung von insulin zur behandlung von knorpelkrankheiten
WO2001092334A1 (fr) 2000-06-02 2001-12-06 Novo Nordisk A/S Liberation glucose-dependante d'insuline par des derives d'insuline detectant le glucose
CN1141974C (zh) 2000-06-07 2004-03-17 张昊 结肠定位释放的口服生物制剂
KR100508695B1 (ko) 2001-02-13 2005-08-17 한국과학기술연구원 인슐린의 경구투여용 제형과 그의 제조방법
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
WO2002067969A2 (fr) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Compositions d'insuline stabilisees
CN1160122C (zh) 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
MY137181A (en) 2001-05-21 2009-01-30 Nektar Therapeutics Pulmonary administration of chemically modified insulin
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
EP1423136A4 (fr) 2001-08-10 2007-07-25 Epix Pharm Inc Conjugues de polypeptides ayant des demi-vies de circulation accrues
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
PT1430082E (pt) 2001-09-07 2010-01-15 Biocon Ltd Métodos de síntese de conjugados de polipéptido de insulina-oligómero, e conjugados de polipéptido de pró-insulina-oligómero e método de síntese dos mesmos
WO2003048195A2 (fr) 2001-12-02 2003-06-12 Novo Nordisk A/S Nouvelles insulines gluco-dependantes
US7317000B2 (en) 2001-12-02 2008-01-08 Novo Nordisk A/S Glucose-dependent insulins
US8535650B2 (en) 2001-12-03 2013-09-17 Soligenix, Inc. Stabilized reverse micelle compositions and uses thereof
EP1456371A1 (fr) 2001-12-05 2004-09-15 Dow Global Technologies Inc. Procede d'immobilisation d'un agent biologique dans une composition de polyurethane-hydrogel, composition preparee a partir de ce procede et applications biomedicales
AU2002346491A1 (en) 2001-12-19 2003-07-09 Eli Lilly And Company Crystalline compositions for controlling blood glucose
EP1545460A4 (fr) 2001-12-20 2005-11-16 Lilly Co Eli Molecule d'insuline a duree d'action prolongee
UA46669C2 (uk) 2001-12-29 2005-12-15 Товариство З Обмеженою Відповідальністю "Мако" Спосіб приготування готової лікарської форми інсуліну пролонгованої дії
US8003605B2 (en) 2002-03-13 2011-08-23 Novo Nordisk A/S Minimising body weight gain in insulin treatment
EP1506003A1 (fr) 2002-05-07 2005-02-16 Novo Nordisk A/S Preparations solubles comprenant de l'insuline aspart et de l'insuline detemir
ATE496064T1 (de) 2002-05-07 2011-02-15 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
US7601688B2 (en) 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
CN1165549C (zh) 2002-06-15 2004-09-08 江苏万邦生化医药股份有限公司 胰岛素的纯化方法
AU2003272347A1 (en) 2002-09-17 2004-04-08 Merck And Co., Inc. Removal of aldehyde impurity by reactive polystyrene resin
US20050065066A1 (en) * 2002-12-20 2005-03-24 Kaarsholm Niels Christian Stabilised insulin compositions
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
US20040185068A1 (en) 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
CN1812808B (zh) 2003-06-03 2012-07-04 诺沃挪第克公司 稳定化的药物肽组合物
PL1633391T3 (pl) 2003-06-03 2012-03-30 Novo Nordisk As Stabilizowane farmaceutycznie kompozycje peptydowe
DE602004015980D1 (de) 2003-06-17 2008-10-02 Sembiosys Genetics Inc Verfahren zur insulinproduktion in pflanzen
US20050054818A1 (en) 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
EP1644411A2 (fr) 2003-07-11 2006-04-12 Novo Nordisk A/S Compositions d'insuline stabilisee
AU2004261319B2 (en) 2003-07-25 2010-12-23 Conjuchem Biotechnologies Inc. Long lasting insulin derivatives and methods thereof
BRPI0413276B8 (pt) 2003-08-05 2021-05-25 Novo Nordisk As derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica
US20060198819A1 (en) 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
WO2005016312A1 (fr) 2003-08-13 2005-02-24 Nobex Corporation Formulation de dosage de solides de sels d'acides gras destinee a des agents therapeutiques
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
US20050118206A1 (en) 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
EP1687428A1 (fr) 2003-11-14 2006-08-09 Novo Nordisk A/S Procede de fabrication d'insuline acylee
CN104826116A (zh) 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
WO2005058961A2 (fr) 2003-12-12 2005-06-30 Amgen Inc. Anticorps anti-galanine et leurs utilisations
DE10358387A1 (de) 2003-12-13 2005-07-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulver enthaltend niedermolekulares Dextran und Verfahren zu deren Herstellung
JP4792457B2 (ja) 2004-03-26 2011-10-12 ユニヴァーシタ’デグリ ステュディ ディ パルマ 高度に呼吸に適したインスリンのマイクロ粒子
US20050232981A1 (en) 2004-04-15 2005-10-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
MXPA06012980A (es) 2004-05-10 2007-06-12 Nastech Pharm Co Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea.
JP2008505866A (ja) 2004-07-09 2008-02-28 ノボ　ノルディスク　アクティーゼルスカブ インスリンを含有する薬学的製剤
WO2006014673A2 (fr) 2004-07-19 2006-02-09 Nobex Corporation Conjugues insuline-oligomere, preparations et utilisations de ceux-ci
EP1789074A4 (fr) 2004-08-09 2009-08-12 Alios Biopharma Inc Variants de polypeptides synthetiques hyperglycosyles resistants a la protease, formulations orales et leurs procedes d'utilisation
EP2314298B1 (fr) 2004-08-23 2015-05-27 MannKind Corporation Microparticules comprenant des sels de diketopiperazine permettant l'administration de médicaments
DE602005010899D1 (de) 2004-09-27 2008-12-18 Sigmoid Pharma Ltd Mikrokapseln mit einem methylxanthin und einem kortikosteroid
CN101060856B (zh) * 2004-11-22 2011-01-19 诺和诺德公司 可溶、稳定的含胰岛素制剂
EP1817050B1 (fr) 2004-12-03 2015-04-15 Rhode Island Hospital Diagnostic et traitement de la maladie d'alzheimer
WO2006079641A2 (fr) 2005-01-27 2006-08-03 Novo Nordisk A/S Derives d'insuline conjugues avec des polymeres ramifies structurellement bien definis
JP4933455B2 (ja) 2005-02-02 2012-05-16 ノヴォ ノルディスク アー／エス 新規のインスリン誘導体
EP2292653B1 (fr) 2005-02-02 2014-05-21 Novo Nordisk A/S Nouveaux dérivés d'insuline
US20090123563A1 (en) 2005-02-07 2009-05-14 Novo Nordisk A/S Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand
WO2006086856A1 (fr) 2005-02-15 2006-08-24 Messadek, Jallal Compositions therapeutiques combinees et leurs procedes d’utilisation
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
WO2006097521A1 (fr) 2005-03-18 2006-09-21 Novo Nordisk A/S Insuline monocatenaire pegylee
WO2006103657A2 (fr) 2005-03-31 2006-10-05 Dexcel Pharma Technologies Ltd. Composition solide de distribution intra-buccale d'insuline
US20080200383A1 (en) 2005-04-08 2008-08-21 Amylin Pharmaceuticals, Inc. Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent
EP1888118B1 (fr) 2005-05-25 2016-08-17 Novo Nordisk A/S Formulations de polypeptides stabilisées avec de l'éthylènediamine
WO2007006320A1 (fr) 2005-07-12 2007-01-18 Sherine Hassan Abbas Helmy Liquide buvable et gélules orales d'insuline
WO2007041481A1 (fr) 2005-09-29 2007-04-12 Biodel, Inc. Preparations d'insuline a action rapide et prolongee
JP4710533B2 (ja) 2005-10-07 2011-06-29 株式会社豊田自動織機 牽引車両のドローバー装置
JP2009512709A (ja) 2005-10-20 2009-03-26 エムディーアールエヌエー，インコーポレイテッド 速効型インスリンの経鼻投与
PL1969004T3 (pl) 2005-12-28 2012-01-31 Novo Nordisk As Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji
WO2007081824A2 (fr) 2006-01-06 2007-07-19 Case Western Reserve University Protéines résistantes à la fibrillation
US20090069216A1 (en) 2006-02-21 2009-03-12 Novo Nordisk A/S Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof
DE602007009496D1 (de) 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
JP2009530242A (ja) 2006-03-13 2009-08-27 ノボ・ノルデイスク・エー／エス アシル化単鎖インスリン
US20090099065A1 (en) 2006-03-13 2009-04-16 Novo Nordisk A/S Acylated Single Chain Insulin
EP2024390B1 (fr) 2006-05-09 2015-08-19 Novo Nordisk A/S Dérivé insulinique
EP2386572B1 (fr) 2006-05-09 2015-07-08 Novo Nordisk A/S Dérivé d'insuline
WO2008015099A2 (fr) 2006-07-31 2008-02-07 Novo Nordisk A/S Insulines pegylées à extensions
ES2601839T3 (es) 2006-09-22 2017-02-16 Novo Nordisk A/S Análogos de insulina resistentes a proteasas
WO2008043033A2 (fr) 2006-10-04 2008-04-10 Case Western Reserve University Insuline et analogues de l'insuline résistants à la fibrillation
EP2152243A2 (fr) * 2007-04-30 2010-02-17 Novo Nordisk A/S Solutions et compositions hautement concentrées en insuline
JP5496082B2 (ja) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
EP2514406A1 (fr) 2007-06-01 2012-10-24 Novo Nordisk A/S Préconcentrés spontanément dispersibles comprenant un médicament peptidique dans un support solide ou semi-solide
EP2497462A1 (fr) 2007-06-01 2012-09-12 Novo Nordisk A/S Compositions pharmaceutiques stables non aqueuses
WO2008152106A1 (fr) 2007-06-13 2008-12-18 Novo Nordisk A/S Formulation pharmaceutique contenant un dérivé d'insuline
WO2009010428A1 (fr) 2007-07-16 2009-01-22 Novo Nordisk A/S Analogues pegylés de l'insuline, stabilisés vis-à-vis des protéases
CN101778862B (zh) 2007-08-13 2014-12-17 诺沃-诺迪斯克有限公司 快速作用的胰岛素类似物
AU2008288413B2 (en) 2007-08-15 2013-09-26 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
US8962794B2 (en) 2007-08-15 2015-02-24 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
US20090087484A1 (en) 2007-09-28 2009-04-02 Alza Corporation Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
CA2705821A1 (fr) 2007-11-16 2009-05-22 Novo Nordisk A/S Composition pharmaceutique contenant de l'insuline et peptide insulinotropique
EP2254905B1 (fr) 2008-03-14 2016-12-14 Novo Nordisk A/S Analogues de l insuline stabilisés une protéase
DK2254906T3 (en) 2008-03-18 2017-01-23 Novo Nordisk As Protease-stabilized acylated insulin analogues
WO2009129250A2 (fr) 2008-04-14 2009-10-22 Case Western Reserve University Analogues de l'insuline à prendre au moment des repas de stabilité améliorée
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
WO2010049488A1 (fr) 2008-10-30 2010-05-06 Novo Nordisk A/S Traitement du diabète à l’aide d’injections d’insuline avec une fréquence inférieure à une injection par jour
EP2370059A1 (fr) 2008-11-28 2011-10-05 Novo Nordisk A/S Compositions pharmaceutiques appropriées pour une administration orale de dérivé de peptide d'insuline
US20110294729A1 (en) 2008-12-09 2011-12-01 Novo Nordisk A/S Novel Insulin Analogues
MX2011008416A (es) 2009-02-13 2011-09-08 Boehringer Ingelheim Int Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos.
WO2011033019A1 (fr) 2009-09-16 2011-03-24 Novo Nordisk A/S Compositions pharmaceutiques liquides non aqueuses stables comprenant une insuline
CN102665676B (zh) 2009-11-02 2015-04-01 诺沃-诺迪斯克有限公司 非共价结合的白蛋白和酰化胰岛素的药物溶液
CA2786953A1 (fr) 2010-01-12 2011-07-21 Florian Anders Foeger Compositions pharmaceutiques pour l'administration orale de peptides de l'insuline
CN102947331B (zh) 2010-06-23 2016-08-03 诺沃—诺迪斯克有限公司 包含额外的二硫键的胰岛素类似物
AU2011269000C1 (en) 2010-06-23 2015-10-08 Novo Nordisk A/S Insulin derivatives containing additional disulfide bonds
US20140315797A1 (en) 2010-10-15 2014-10-23 Peter Madsen Novel N-Terminally Modified Insulin Derivatives
CN103249427A (zh) * 2010-12-14 2013-08-14 诺沃—诺迪斯克有限公司 速效胰岛素联合长效胰岛素
JP6058646B2 (ja) 2011-06-15 2017-01-11 ノヴォ ノルディスク アー／エス 多置換インスリン
CA2870313A1 (fr) * 2012-04-11 2013-10-17 Novo Nordisk A/S Formulations a base d'insuline
WO2014009316A1 (fr) 2012-07-09 2014-01-16 Novo Nordisk A/S Nouvelle utilisation de dérivés d'insuline
WO2014177623A1 (fr) 2013-04-30 2014-11-06 Novo Nordisk A/S Schéma d'administration d'un nouveau type
WO2014202780A1 (fr) 2013-06-21 2014-12-24 Novo Nordisk A/S Nouvelles utilisations d'agonistes du récepteur glp-1 chez des patients traités par insuline et/ou souffrant d'un diabète de type 1
AU2014333979B2 (en) * 2013-10-07 2018-02-15 Novo Nordisk A/S Novel derivative of an insulin analogue
CN104587455A (zh) * 2013-10-31 2015-05-06 江苏万邦生化医药股份有限公司 一种胰岛素制剂
FR3013049B1 (fr) 2013-11-14 2015-11-13 You-Ping Chan Analogue de l'insuline glargine
WO2015104311A1 (fr) * 2014-01-09 2015-07-16 Sanofi Formulations pharmaceutiques stabilisées sans glycérol d'analogues de l'insuline et/ou de dérivés de l'insuline
US20170028031A1 (en) 2014-03-07 2017-02-02 Klavs Holger Jørgensen Novel fast acting insulin preparations
JO3624B1 (ar) 2014-05-08 2020-08-27 Lilly Co Eli تركيبات إنسولين سريعة المفعول
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
HUE060149T2 (hu) * 2016-12-16 2023-02-28 Novo Nordisk As Inzulint tartalmazó gyógyászati készítmények

Also Published As

Publication number Publication date
CN115154591B (zh) 2023-04-14
RS63773B1 (sr) 2022-12-30
JP6690062B2 (ja) 2020-04-28
HUE060149T2 (hu) 2023-02-28
AU2017378102A1 (en) 2019-05-30
CA3046583A1 (fr) 2018-06-21
TW202003017A (zh) 2020-01-16
JP2020105227A (ja) 2020-07-09
US10596231B2 (en) 2020-03-24
CN115154591A (zh) 2022-10-11
RU2019118696A3 (fr) 2021-03-19
BR112019011761A2 (pt) 2019-11-05
US10265385B2 (en) 2019-04-23
CL2019001586A1 (es) 2019-08-16
EP3821905A1 (fr) 2021-05-19
SA520420276B1 (ar) 2022-12-05
IL267224B2 (en) 2023-10-01
SI3554534T1 (sl) 2021-09-30
MY200748A (en) 2024-01-13
PL3821905T3 (pl) 2022-12-27
ZA202406617B (en) 2025-03-26
RU2019118696A (ru) 2021-01-18
ZA201903425B (en) 2024-12-18
RS62295B1 (sr) 2021-09-30
MY194504A (en) 2022-11-30
IL267224B1 (en) 2023-06-01
ES2930149T3 (es) 2022-12-07
IL300839B2 (en) 2024-04-01
IL300839A (en) 2023-04-01
US20180303908A1 (en) 2018-10-25
KR102580007B1 (ko) 2023-09-19
EP3554534B1 (fr) 2021-06-23
PE20210857A1 (es) 2021-05-18
DK3821905T3 (da) 2022-11-14
HRP20211281T1 (hr) 2021-11-12
US20200384088A1 (en) 2020-12-10
US20240424064A1 (en) 2024-12-26
ZA202406618B (en) 2025-03-26
IL300839B1 (en) 2023-12-01
WO2018109162A1 (fr) 2018-06-21
MX2021002083A (es) 2021-04-28
PH12019501363A1 (en) 2020-02-24
TWI700091B (zh) 2020-08-01
MX380480B (es) 2025-03-12
KR20210091350A (ko) 2021-07-21
DK3554534T3 (da) 2021-08-23
ES2886837T3 (es) 2021-12-21
CO2019006017A2 (es) 2019-10-31
SA519401933B1 (ar) 2024-01-25
CN110087674A (zh) 2019-08-02
RU2758367C2 (ru) 2021-10-28
MX2019006463A (es) 2019-08-14
AU2022218612B2 (en) 2024-03-07
TWI700092B (zh) 2020-08-01
US20190183979A1 (en) 2019-06-20
EP3821905B1 (fr) 2022-10-12
EP3554534A1 (fr) 2019-10-23
US20220202909A1 (en) 2022-06-30
AU2022218612A1 (en) 2022-09-22
TW201827071A (zh) 2018-08-01
PT3554534T (pt) 2021-11-05
KR102374354B1 (ko) 2022-03-15
JP2020502145A (ja) 2020-01-23
CN110087674B (zh) 2023-01-03
HRP20221324T1 (hr) 2022-12-23
AU2017378102B2 (en) 2022-10-13
PE20191205A1 (es) 2019-09-10
KR20190097001A (ko) 2019-08-20
PL3554534T3 (pl) 2021-12-13
JP6788139B2 (ja) 2020-11-18
IL267224A (en) 2019-08-29
US20180169190A1 (en) 2018-06-21
HUE055231T2 (hu) 2021-11-29

Similar Documents

Publication Publication Date Title
MA49116A (fr) Compositions pharmaceutiques contenant de l'insuline
MA41901A (fr) Compositions contenant de l'ibrutinib
EP3565550A4 (fr) Compositions pharmaceutiques contenant du méloxicam
EP3256138A4 (fr) Compositions pharmaceutiques contenant du méloxicam
EP3493799A4 (fr) Composition pharmaceutique decannabis
EP3621621A4 (fr) Compositions pharmaceutiques contenant du méloxicam
IL257531A (en) Therapeutic combinations comprising anti-folr1 immunoconjugates
EP3513809A4 (fr) Composition médicinale
EP3493798A4 (fr) Composition pharmaceutique decannabis
EP3454899C0 (fr) Composition pharmaceutique
DK3532029T3 (da) Flydende farmaceutisk sammensætning
EP2949647A4 (fr) Composé d'aminopyrimidine phényle deutérié et composition pharmaceutique le contenant
EP3412660A4 (fr) Dérivé de sulfonamide et composition pharmaceutique le contenant
PL3518892T3 (pl) Preparat farmaceutyczny zawierający związek insuliny
MA49947A (fr) Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
EP3318282A4 (fr) Vecteur d'administration de médicament, et composition le contenant
EP3412344A4 (fr) Composition d'agent extincteur
EP3402470A4 (fr) Composition pharmaceutique stable
EP3360551A4 (fr) Composition pharmaceutique contenant un composé d'arylalkylamine
EP2968195A4 (fr) Formulations pharmaceutiques contenant un glycosaminoglycane
PL4023651T3 (pl) Aktywna optycznie pochodna piranochromenylofenolu i kompozycja farmaceutyczna ją zawierająca
EP3646863A4 (fr) Composition pharmaceutique
EP3646867A4 (fr) Composition pharmaceutique
EP3524250A4 (fr) Composition pharmaceutique
MA45158A (fr) Composition pharmaceutique comprenant de l'éteplirsen